Pharma stocks are in focus as UBS cited intensifying competition in the generic GLP-1 segment, while turning selective on key names based on pipeline strength, execution visibility, and reliance on one-off drivers.
Pharma stocks are in focus as UBS cited intensifying competition in the generic GLP-1 segment, while turning selective on key names based on pipeline strength, execution visibility, and reliance on one-off drivers.